In the article “Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial” (J Am Heart Assoc. 2015;4:e002015. DOI: 10.1161/JAHA.115.002015), which published online December 1, 2015 and appeared in the December 23, 2015 issue of the journal, a correction was needed.
In Table 3 in the publication, there was an error in the stroke/systemic embolism hazard ratio in patients with a history of hypertension. In the article, it was listed as 0.82 (0.68–0.10); however, the correct hazard ratio (95% CI) is 0.82 (0.68–1.00).
The authors apologize for the error.
The online version of the article has been updated and is available at https://www.ahajournals.org/doi/10.1161/JAHA.115.002015
(J Am Heart Assoc. 2021;10:e014653. DOI: 10.1161/JAHA.119.014653.)